Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries

References

• Modjarrad K, Giersing B, Kaslow DC, et al. WHO consultation on respiratory syncytial virus vaccine development report from a World Health Organization meeting held on 23–24 march 2015. Vaccine. 2016;34(2):190–197.
   PubMed Web of Science ®Google Scholar
• Legand A, Briand S, Shindo N, et al. Addressing the public health burden of respiratory viruses: the battle against respiratory viruses (BRaVE) initiative. Future Virol. 2013;8(10):953–968.
   Web of Science ®Google Scholar
• Shi T, McAllister DA, O’Brien KL, et al., Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 390(10098): 946–958. 2017.
   PubMed Web of Science ®Google Scholar
• Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545–1555.
   PubMed Web of Science ®Google Scholar
• Geoghegan S, Erviti A, Caballero MT, et al. Mortality due to respiratory syncytial virus. Burden and risk factors. Am J Respir Crit Care Med. 2017;195(1):96–103.
   PubMed Web of Science ®Google Scholar
• DAC List of ODA recipients. Effective for reporting on 2020 flows. http://www.oecd.org/dac/financing-sustainable-development/development-finance-standards/DAC-List-of-ODA-Recipients-for-reporting-2020-flows.pdf, accessed on 12th May 2020.
   Google Scholar
• Chanock R, Roizman B, Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg. 1957;66(3):281–290.
   PubMed Web of Science ®Google Scholar
• Chanock R, Finberg L. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children. Am J Hyg. 1957;66(3):291–300.
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89(4):422–434.
   PubMed Web of Science ®Google Scholar
• The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3):531–537.
   Web of Science ®Google Scholar
• Luna MS, Manzoni P, Paes B, et al. Expert consensus on palivizumab use for respiratory syncytial virus in developed countries. Paediatr Respir Rev. 2020;33:35–44.
   PubMed Web of Science ®Google Scholar
• Paes B, Mitchell I, Li A, et al. A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian registry of Palivizumab (CARESS). Eur J Clin Microbiol Infect Dis. 2012;31(10):2703–2711.
   PubMed Web of Science ®Google Scholar
• Frogel M, Nerwen C, Cohen A, et al. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab outcomes registry. J Perinatol. 2008;28(7):511–517.
   PubMed Web of Science ®Google Scholar
• Parnes C, Guillermin J, Habersang R, et al. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab outcomes registry. Pediatr Pulmonol. 2003;35(6):484–489.
   PubMed Web of Science ®Google Scholar
• Oh PI, Lanctôt KL, Yoon A, et al. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J. 2002;21(6):512–518.
   PubMed Web of Science ®Google Scholar
• Mitchell I, Paes BA, Li A, et al. CARESS: the Canadian registry of palivizumab. Pediatr Infect Dis J. 2011;30(8):651–655. .
   PubMed Web of Science ®Google Scholar
• EAF S, Bont L, Manzoni P, et al. Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children. Infect Dis Ther. 2018;7(1):87–120.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO preferred product characteristics for respiratory syncytial virus (RSV) vaccines. http://www.who.int/immunization/documents/en/, accessed on 7th May 2020.
   Google Scholar
• Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle, et al., Respiratory syncytial virus seasonality: A global overview. J Infect Dis. 217(9): 1356–1364. 2018.
   PubMed Web of Science ®Google Scholar
• Rima B, Collins P, Easton A, et al. ICTV Virus Taxonomy Profile: pneumoviridae. J Gen Virol. 2017;98(12):2912–2913.
   PubMed Web of Science ®Google Scholar
• Vandini S, Biagi C, Lanari M. Respiratory syncytial virus: the influence of serotype and genotype variability on clinical course of infection. Int J Mol Sci. 2017;18(8):1717.
   PubMed Web of Science ®Google Scholar
• Schobel SA, Stucker KM, Moore ML, et al. Respiratory syncytial virus whole-genome sequencing identifies convergent evolution of sequence duplication in the C-terminus of the G gene. Sci Rep. 2016;6:26311.
   PubMed Web of Science ®Google Scholar
• Meer HC, Ingelfinger JR. Viral bronchiolitis in children. N Engl J Med. 2016;374(1):62–72.
   PubMed Web of Science ®Google Scholar
• White LJ, Waris M, Cane PA, et al. The transmission dynamics of groups A and B human respiratory syncytial virus (hRSV) in England & Wales and Finland: seasonality and cross-protection. Epidemiol Infect. 2005;133(2):279–289.
   PubMed Web of Science ®Google Scholar
• Agoti CN, Otieno JR, Munywoki PK, et al. Local evolutionary patterns of human respiratory syncytial virus derived from whole-genome sequencing. J Virol. 2015;89(7):3444–3454.
   PubMed Web of Science ®Google Scholar
• Yui I, Fujino M, Sawada A, et al. Novel clinical features of recurrent human respiratory syncytial virus infections. J Med Virol. 2014;86(9):1629–1638.
   PubMed Web of Science ®Google Scholar
• San-Juan-Vergara H, Peeples ME. Importance of virus characteristics in respiratory syncytial virus-induced disease. Immunol Allergy Clin North Am. 2019;39(3):321–334.
   PubMed Web of Science ®Google Scholar
• Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev. 2014;35(12):519–530.
   PubMedGoogle Scholar
• Knudson CJ, Hartwig SM, Meyerholz DK, et al. RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets. PLoS Pathog. 2015;11(3):e1004757.
   PubMed Web of Science ®Google Scholar
• Fleming EH, Ochoa EE, Nichols JE, et al. Reduced activation and proliferation of human lymphocytes exposed to respiratory syncytial virus compared to cells exposed to influenza virus. J Med Virol. 2018;90(1):26–33.
   PubMed Web of Science ®Google Scholar
• Le Nouën C, Hillyer P, Levenson E, et al. Lack of activation marker induction and chemokine receptor switch in human neonatal myeloid dendritic cells in response to human respiratory syncytial virus. J Virol. 2019;93(22):e01216–19.
   PubMed Web of Science ®Google Scholar
• Céspedes PF, Susan M Bueno SM, Ramírez BA, et al. Surface expression of the hRSV nucleoprotein impairs immunological synapse formation with T cells. Proc Natl Acad Sci USA. 2014;111(31):E3214–23.
   PubMed Web of Science ®Google Scholar
• Ohuma EO, Okiro EA, Ochola R, et al. The natural history of respiratory syncytial virus in a birth cohort: the influence of age and previous infection on reinfection and disease. Am J Epidemiol. 2012;176(9):794–802.
   PubMed Web of Science ®Google Scholar
• Bont L, Checchia PA, Fauroux B, et al., Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in Western countries. Infect Dis Ther. 5(3): 271–298. 2016. .
   PubMed Web of Science ®Google Scholar
• Haber N. Respiratory syncytial virus Infection in elderly adults. Med Mal Infect. 2018;48(6):377–382.
   PubMed Web of Science ®Google Scholar
• Paes B, Fauroux B, Figueras-Aloy J, et al., Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among infants with chronic lung disease. Infect Dis Ther. 5(4): 453–471. 2016.
   PubMed Web of Science ®Google Scholar
• Checchia PA, Paes B, Bont L, et al., Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among Infants with congenital heart disease. Infect Dis Ther. 6(1): 37–56. 2017.
   PubMed Web of Science ®Google Scholar
• Mansbach JM, Hasegawa K, Piedra PA, et al. Severe coronavirus bronchiolitis in the pre-COVID-19 era. Pediatrics. 2020 Jun 10;146:e20201267.
   PubMed Web of Science ®Google Scholar
• Peltola V, Ruuskanen O. Editorial commentary: respiratory viral infections in developing countries: common, severe, and unrecognized. Clin Infect Dis. 2008;46(1):58–60.
   PubMed Web of Science ®Google Scholar
• Florin TA, Plint AC, Zorc JJ. Viral bronchiolitis. Lancet. 2017;389(10065):211–224.
   PubMed Web of Science ®Google Scholar
• Nakouné E, Tricou V, Manirakiza A, et al. First introduction of pandemic influenza A/H1N1 and detection of respiratory viruses in pediatric patients in Central African Republic. Virol J. 2013;10:49.
   PubMed Web of Science ®Google Scholar
• Yassine HM, Sohail MU, Younes N, et al. Systematic review of the respiratory syncytial virus (RSV) prevalence, genotype distribution, and seasonality in children from the Middle East and North Africa (MENA) region. Microorganisms. 2020;8(5):E713.
   PubMed Web of Science ®Google Scholar
• Colocho Zelaya EA, Pettersson CA, Forsgren M, et al. Respiratory syncytial virus infection in hospitalized patients and healthy children in El Salvador. Am J Trop Med Hyg. 1994;51(5):577–584.
   PubMed Web of Science ®Google Scholar
• Broor S, Campbell H, Hirve S, et al. Leveraging the global influenza surveillance and response system for global respiratory syncytial virus surveillance-opportunities and challenges. Influenza Other Respir Viruses. 2019 Aug 24 Epub ahead of print. doi:10.1111/irv.12672.
   PubMed Web of Science ®Google Scholar
• Campbell H, Bont L, Nair H. Respiratory syncytial virus (RSV) disease - new data needed to guide future policy. J Glob Health. 2015;5(2):020101.
   PubMed Web of Science ®Google Scholar
• Schuh S, Babl FE, Dalziel SR, et al. Practice variation in acute bronchiolitis: a pediatric emergency research networks study. Pediatrics. 2017;140(6):e20170842. pii.
   PubMed Web of Science ®Google Scholar
• Freire G, Kuppermann N, Zemek R, et al. Predicting escalated care in Infants with bronchiolitis. Pediatrics. 2018 Sep;142(3):e20174253. pii.
   PubMed Web of Science ®Google Scholar
• Caserta MT, Qiu X, Tesini B, et al. Development of a global respiratory severity score for respiratory syncytial virus infection in infants. J Infect Dis. 2017;215(5):750–756.
   PubMed Web of Science ®Google Scholar
• Hogan CA, Caya C, Papenburg J. Rapid and simple molecular tests for the detection of respiratory syncytial virus: a review. Expert Rev Mol Diagn. 2018;18(7):617–629.
   PubMed Web of Science ®Google Scholar
• Scheltema NM, Gentile A, Lucion F, et al. Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series. Lancet Glob Health. 2017;5(10):e984–91.
   PubMed Web of Science ®Google Scholar
• Harper BD, Nganga W, Armstrong R, et al. Where are the paediatricians? An international survey to understand the global paediatric workforce. BMJ Paediatr Open. 2019;3(1):bmjpo-2018-000397.
   PubMedGoogle Scholar
• Nair H, Simões EA, Rudan I, et al. Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. Lancet. 2013;381(9875):1380–1390.
   PubMed Web of Science ®Google Scholar
• Simões EA, DeVincenzo JP, Boeckh M, et al. Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis. 2015;211(Suppl 1):S1–20.
   PubMed Web of Science ®Google Scholar
• Simões EA, Mutyara K, Soh S, et al. The epidemiology of respiratory syncytial virus lower respiratory tract infections in children less than 5 years of age in Indonesia. Pediatr Infect Dis J. 2011;30(9):778–784.
   PubMed Web of Science ®Google Scholar
• Fauroux B, EAF S, Checchia PA, et al., The burden and long-term respiratory morbidity associated with respiratory syncytial virus infection in early childhood. Infect Dis Ther. 6(2): 173–197. 2017.
   PubMed Web of Science ®Google Scholar
• Carbonell-Estrany X, Pérez-Yarza EG, García LS, et al. Long-term burden and respiratory effects of respiratory syncytial virus hospitalization in preterm infants-the SPRING Study. PLoS One. 2015;10(5):e0125422.
   PubMed Web of Science ®Google Scholar
• Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354(9178):541–545.
   PubMed Web of Science ®Google Scholar
• Sigurs N, Aljassim F, Kjellman B, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax. 2010;65(12):1045–1052.
   PubMed Web of Science ®Google Scholar
• Coutts J, Fullarton J, Morris C, et al. Association between respiratory syncytial virus hospitalization in infancy and childhood asthma. Pediatr Pulmonol. 2020;55(5):1104–1110.
   PubMed Web of Science ®Google Scholar
• Korppi M, Piippo-Savolainen E, Korhonen K, et al. Respiratory morbidity 20 years after RSV infection in infancy. Pediatr Pulmonol. 2004;38(2):155–160.
   PubMed Web of Science ®Google Scholar
• Greenough A, Alexander J, Boit P, et al. School age outcome of hospitalisation with respiratory syncytial virus infection of prematurely born Infants. Thorax. 2009;64(6):490–495.
   PubMed Web of Science ®Google Scholar
• Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368(19):1791–1799.
   PubMed Web of Science ®Google Scholar
• Poulsen A, Stensballe LG, Nielsen J, et al. Long-term consequences of respiratory syncytial virus acute lower respiratory tract infection in early childhood in Guinea-bissau. Pediatr Infect Dis J. 2006;25(11):1025–1031.
   PubMed Web of Science ®Google Scholar
• Gbadero DA, Johnson AW, Aderele WI, et al. Microbial inciters of acute asthma in urban Nigerian children. Thorax. 1995;50(7):739–745.
   PubMed Web of Science ®Google Scholar
• Guo J, Zhu W, Wang H, et al. Risk factors and prognosis of recurrent wheezing in Chinese young children: a prospective cohort study. Allergy Asthma Clin Immunol. 2019;15:38.
   PubMed Web of Science ®Google Scholar
• Rattanadilok Na Bhuket T, Sunakorn P, Suwanjutha S, et al. Wheezing–associated lower respiratory infections in under 5-year-old children: study in Takhli district hospital. J Med Assoc Thai. 2002;85(Suppl 4):S1247–51.
   PubMedGoogle Scholar
• Karaman O, Tatli Güneş B, Erbaytaktar Z, et al. Recurrence of wheezing episodes in children with respiratory syncytial virus and non- respiratory syncytial virus bronchiolitis. Turkiye Klinikleri J Med Sci. 2011;31(6):1507–1513.
   Google Scholar
• Fischer GB, Sarria EE, Camargos P, et al. Childhood asthma in low and middle-income countries: where are we now? Paediatr Respir Rev. 2019;31:52–57.
   PubMed Web of Science ®Google Scholar
• Paes B, Carbonell-Estrany X. Respiratory syncytial virus prophylaxis for children with chronic lung disease: have we got the criteria right? Expert Rev Anti Infect Ther. 2019;17(4):211–222.
   PubMed Web of Science ®Google Scholar
• Figueras-Aloy J, Manzoni P, Paes B, et al., Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among preterm infants without chronic lung disease or congenital heart disease. Infect Dis Ther. 5(4): 417–452. 2016. .
   PubMed Web of Science ®Google Scholar
• Manzoni P, Figueras-Aloy J, EAF S, et al. Defining the incidence and associated morbidity and mortality of severe respiratory syncytial virus infection among children with chronic diseases. Infect Dis Ther. 2017;6(3):383–411.
   PubMed Web of Science ®Google Scholar
• Mitra S, El Azrak M, McCord H, et al. Hospitalization for respiratory syncytial virus in children with down syndrome less than 2 years of age: a systematic review and meta-analysis. J Pediatr. 2018;203:92–100.e3.
   PubMed Web of Science ®Google Scholar
• Paes BA, Saleem M, Li A, et al. Respiratory syncytial virus prophylaxis in immunocompromised children: outcomes from the Canadian RSV evaluation study of Palivizumab registry over twelve seasons (2005-2017). Pediatr Infect Dis J. 2020;39(6):539–545.
   PubMed Web of Science ®Google Scholar
• Groves HE, Jenkins MM, et al. Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland. Pediatr Pulmonol. 2016;51(4):379–385.
   PubMed Web of Science ®Google Scholar
• Wang DY, Saleem M, Paes BA, et al. Respiratory syncytial virus prophylaxis in neurologic and muscular disorders in the Canadian respiratory syncytial virus evaluation study of Palivizumab. Pediatr Infect Dis J. 2019;38(8):775–780.
   PubMed Web of Science ®Google Scholar
• Shi T, Balsells E, Wastnedge E, et al., Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: systematic review and meta-analysis. J Glob Health. 5(2): 020416. 2015.
   PubMed Web of Science ®Google Scholar
• Rossi GA, Medici MC, Arcangeletti MC, et al. Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr. 2007;166(12):1267–1272.
   PubMed Web of Science ®Google Scholar
• Jansson L, Nilsson P, Olsson M. Socioeconomic environmental factors and hospitalization for acute bronchiolitis during infancy. Acta Paediatr. 2002;91(3):335–338.
   PubMed Web of Science ®Google Scholar
• Cilla G, Sarasua A, Montes M, et al. Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain. Epidemiol Infect. 2006;134(3):506–513.
   PubMed Web of Science ®Google Scholar
• Kristensen K, Fisker N, Haerskjold A, et al. Caesarean section and hospitalization for respiratory syncytial virus infection: a population-based study. Pediatr Infect Dis J. 2015;34(2):145–148.
   PubMed Web of Science ®Google Scholar
• Belderbos ME, Houben ML, Wilbrink B, et al. Cord blood vitamin D deficiency is associated with respiratory syncytial virus bronchiolitis. Pediatrics. 2011;127(6):e1513–20.
   PubMed Web of Science ®Google Scholar
• Vandini S, Corvaglia L, Alessandroni R, et al. Respiratory syncytial virus infection in infants and correlation with meteorological factors and air pollutants. Ital J Pediatr. 2013;39(1):1.
   PubMedGoogle Scholar
• Chavez D, Gonzales-Armayo V, Mendoza E, et al. Estimation of influenza and respiratory syncytial virus hospitalizations using sentinel surveillance data-La Paz, Bolivia. 2012-2017. Influenza Other Respir Viruses. 2019;13(5):477–483.
   PubMed Web of Science ®Google Scholar
• Kubale J, Kuan G, Gresh L, et al. Assessing the incidence of symptomatic respiratory syncytial virus illness within a prospective birth cohort in Managua, Nicaragua. Clin Infect Dis. 2020;70(10):2029–2035.
   PubMed Web of Science ®Google Scholar
• Awad S, Khader Y, Mansi M, et al. Viral surveillance of children with acute respiratory infection in two main hospitals in Northern Jordan, Irbid, during winter of 2016. J Pediatr Infect Dis. 2020;15(1):1–10.
   PubMed Web of Science ®Google Scholar
• Buchwald AG, Tamboura B, Tennant SM, et al. Epidemiology, risk factors, and outcomes of respiratory syncytial virus infections in newborns in Bamako, Mali. Clin Infect Dis. 2020;70(1):59–66.
   PubMed Web of Science ®Google Scholar
• Weber MW, Milligan P, Hilton S, et al. Risk factors for severe respiratory syncytial virus infection leading to hospital admission in children in the Western region of The Gambia. Int J Epidemiol. 1999;28(1):157–162.
   PubMed Web of Science ®Google Scholar
• Bashir U, Nisar N, Arshad Y, et al. Respiratory syncytial virus and influenza are the key viral pathogens in children <2 years hospitalized with bronchiolitis and pneumonia in Islamabad Pakistan. Arch Virol. 2017;162(3):763–773.
   PubMed Web of Science ®Google Scholar
• Wu A, Budge PJ, Williams J, et al. Incidence and risk factors for respiratory syncytial virus and human metapneumovirus infections among children in the remote highlands of Peru. PLoS One. 2015;10(6):e0130233.
   PubMed Web of Science ®Google Scholar
• Okiro EA, Ngama M, Bett A, et al. Factors associated with increased risk of progression to respiratory syncytial virus-associated pneumonia in young Kenyan children. Trop Med Int Health. 2008;13(7):914–926. .
   PubMed Web of Science ®Google Scholar
• Zhang T, Zhu Q, Zhang X, et al. Clinical characteristics and direct medical cost of respiratory syncytial virus infection in children hospitalized in Suzhou, China. Pediatr Infect Dis J. 2014;33(4):337–341.
   PubMed Web of Science ®Google Scholar
• Khuri-Bulos N, Lawrence L, Piya B, et al. Severe outcomes associated with respiratory viruses in newborns and infants: a prospective viral surveillance study in Jordan. BMJ Open. 2018;8(5):e021898.
   PubMed Web of Science ®Google Scholar
• Ochoa TJ, Bautista R, Dávila C, et al. Respiratory syncytial virus-associated hospitalizations in pre-mature infants in Lima, Peru. Am J Trop Med Hyg. 2014;91(5):1029–1034.
   PubMed Web of Science ®Google Scholar
• Miedema CJ, Kors AW, Tjon A TWE, et al. Medical consumption and socioeconomic effects of infection with respiratory syncytial virus in The Netherlands. Pediatr Infect Dis J. 2001;20(2):160–163.
   PubMed Web of Science ®Google Scholar
• Leidy NK, Margolis MK, Marcin JP, et al. The impact of severe respiratory syncytial virus on the child, caregiver, and family during hospitalization and recovery. Pediatrics. 2005;115(6):1536–1546.
   PubMed Web of Science ®Google Scholar
• Mitchell I, Defoy I, Grubb E. Burden of respiratory syncytial virus hospitalizations in Canada. Can Respir J. 2017;2017:4521302.
   PubMed Web of Science ®Google Scholar
• Heikkinen T, Ojala E, Waris M. Clinical and socioeconomic burden of respiratory syncytial virus infection in children. J Infect Dis. 2017;215(1):17–23.
   PubMed Web of Science ®Google Scholar
• Carbonell-Estrany X, Dall’Agnola A, Fullarton JR, et al. Interaction between healthcare professionals and parents is a key determinant of parental distress during childhood hospitalisation for respiratory syncytial virus infection (European RSV outcomes study [EROS]). Acta Paediatr. 2018;107(5):854–860.
   PubMed Web of Science ®Google Scholar
• Bhuiyan MU, Luby SP, Alamgir NI, et al. Costs of hospitalization with respiratory syncytial virus illness among children aged <5 years and the financial impact on households in Bangladesh, 2010. J Glob Health. 2017;7(1):010412.
   PubMed Web of Science ®Google Scholar
• Swe KT, Rahman MM, Rahman MS, et al. Cost and economic burden of illness over 15 years in Nepal: a comparative analysis. PLoS One. 2018;13(4):e0194564.
   PubMed Web of Science ®Google Scholar
• Synagis (palivizumab) summary of product characteristics. https://www.medicines.org.uk/emc/product/6963, accessed on 18th May 2020.
   Google Scholar
• Feltes TF, Cabalka AK, Meer HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532–540.
   PubMed Web of Science ®Google Scholar
• Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, et al. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J. 2003;22(9):823–827.
   PubMed Web of Science ®Google Scholar
• Anderson EJ, Carosone-Link P, Yogev R, et al. Effectiveness of palivizumab in high-risk infants and children: a propensity score weighted regression analysis. Pediatr Infect Dis J. 2017;36(8):699–704.
   PubMed Web of Science ®Google Scholar
• Lacaze-Masmonteil T, Truffert P, Pinquier D, et al. Lower respiratory tract illness and RSV prophylaxis in very premature infants. Arch Dis Child. 2004;89(6):562–567.
   PubMed Web of Science ®Google Scholar
• Grimaldi M, Gouyon B, Michaut F, et al. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia. Pediatr Infect Dis J. 2004;23(12):1081–1085.
   PubMed Web of Science ®Google Scholar
• Resch B, Gusenleitner W, Müller WD, et al. Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks. Eur J Clin Microbiol Infect Dis. 2006;25(2):120–122.
   PubMed Web of Science ®Google Scholar
• Faldella G, Alessandroni R, Aquilano G, et al. Hospitalization for lower respiratory tract disease in preterm infants: effects of prophylaxis with palivizumab. J Chemother. 2010;22(1):30–35.
   PubMed Web of Science ®Google Scholar
• Turti TV, Baibarina EN, Degtiareva EA, et al. A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian federation. BMC Res Notes. 2012;5:484.
   PubMedGoogle Scholar
• Grimaldi M, Gouyon B, Sagot P, et al. Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia. Pediatr Pulmonol. 2007;42(3):189–192.
   PubMed Web of Science ®Google Scholar
• Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, et al. FLIP-2 study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J. 2008;27(9):788–793.
   PubMed Web of Science ®Google Scholar
• Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab outcomes study group. Pediatr Infect Dis J. 2000;19(11):1068–1071.
   PubMed Web of Science ®Google Scholar
• Medrano López C, García-Guereta L, CIVIC Study Group. Community-acquired respiratory infections in young children with congenital heart diseases in the palivizumab era: the Spanish 4-season civic epidemiologic study. Pediatr Infect Dis J. 2010;29(12):1077–1082.
   PubMed Web of Science ®Google Scholar
• Simon A, Nowak H, Sterz R. Use of palivizumab in Germany: data from 2002-2007. Klin Padiatr. 2011;223(5):292–298.
   PubMed Web of Science ®Google Scholar
• Li A, Wang DY, Lanctôt KL, et al. Comparing first- and second-year palivizumab prophylaxis in patients with hemodynamically significant congenital heart disease in the CARESS database (2005-2015). Pediatr Infect Dis J. 2017;36(5):445–450.
   PubMed Web of Science ®Google Scholar
• Castillo LM, Bugarin G, Arias JC, et al. One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America. J Pediatr (Rio J). 2017;93(5):467–474.
   PubMed Web of Science ®Google Scholar
• Yi H, Lanctôt KL, Bont L, et al. Respiratory syncytial virus prophylaxis in Down Syndrome: a prospective cohort study. Pediatrics. 2014;133(6):1031–1037.
   PubMed Web of Science ®Google Scholar
• Paes B, Mitchell I, Yi H, et al. Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab. Pediatr Infect Dis J. 2014;33(2):e29–33.
   PubMed Web of Science ®Google Scholar
• Kashiwagi T, Okada Y, Nomoto K. Palivizumab prophylaxis against respiratory syncytial virus infection in children with immunocompromised conditions or Down syndrome: a multicenter, post-marketing surveillance in Japan. Paediatr Drugs. 2018 Feb;20(1):97–104.
   PubMed Web of Science ®Google Scholar
• Mitchell I, Paes B, Li A, et al. RSV hospitalization in infants with neuromuscular disease in the Canadian registry of palivizumab after prophylaxis (2005–2012). Eur Respir J. 2013;42:P4319.
   Web of Science ®Google Scholar
• Kim D, Saleem M, Paes B, et al. Respiratory syncytial virus prophylaxis in infants with congenital diaphragmatic hernia in the Canadian respiratory syncytial virus evaluation study of Palivizumab, 2005-2017. Clin Infect Dis. 2019;69(6):980–986.
   PubMed Web of Science ®Google Scholar
• Paes B, Saleem M, Kim D, et al. Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab. Eur J Clin Microbiol Infect Dis. 2019;38(8):1561–1568.
   PubMed Web of Science ®Google Scholar
• Paes B, Mitchell I, Li A, et al. Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Eur J Pediatr. 2012;171(5):833–841.
   PubMed Web of Science ®Google Scholar
• Manzoni P, Paes B, Lanctôt KL, et al. Outcomes of infants receiving palivizumab prophylaxis for respiratory syncytial virus in Canada and Italy: an international, prospective cohort study. Pediatr Infect Dis J. 2017;36(1):2–8.
   PubMed Web of Science ®Google Scholar
• Mitchell I, Paes B, Wong S, et al. Respiratory illness and respiratory syncytial virus (RSV)-related hospitalizations (RSVH) in infants with congenital airway anomalies (CAA) in the CARESS registry (2005–2015). Am J Respir Crit Care Med. 2017;195:A1196.
   Web of Science ®Google Scholar
• Mitchell I, Paes B, Li A, et al. Respiratory syncytial virus (RSV) hospitalization in infants with congenital airway anomalies (CAA) in the Canadian registry of palivizumab (CARESS) after prophylaxis (2005-2012). Eur Respir J. 2014;44:P1259.
   Web of Science ®Google Scholar
• Drummond D, Thumerelle C, Reix P, et al. Effectiveness of palivizumab in children with childhood interstitial lung disease: the French experience. Pediatr Pulmonol. 2016;51(7):688–695. .
   PubMed Web of Science ®Google Scholar
• Paes B, Mitra S. Palivizumab for children with Down syndrome: is the time right for a universal recommendation? Arch Dis Child. 2019;104(8):719–721.
   PubMed Web of Science ®Google Scholar
• Mac S, Sumner A, Duchesne-Belanger S, et al. Cost-effectiveness of palivizumab for respiratory syncytial virus: A systematic review. Pediatrics. 2019;143(5):e20184064. pii.
   PubMed Web of Science ®Google Scholar
• Olchanski N, Hansen RN, Pope E, et al. Palivizumab prophylaxis for respiratory syncytial virus: examining the evidence around value. Open Forum Infect Dis. 2018;5(3):ofy031.
   PubMed Web of Science ®Google Scholar
• Hussman JM, Lanctôt KL, Paes B. The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence. J Med Econ. 2013;16(1):115–124.
   PubMedGoogle Scholar
• Majer I, Pichardo-Piña CA, Sanchez-Casillas JL, et al. Cost-effectiveness of palivizumab in premature infants and children with chronic lung disease in Mexico. Value Health. 2015;18(7):PA834.
   Web of Science ®Google Scholar
• Majer I, Pichardo-Piña CA, Sanchez-Casillas JL, et al. Cost-effectiveness of palivizumab in children with congenital heart disease In Mexico. Value Health. 2015;18(7):PA830.
   Google Scholar
• Salinas-Escudero G, Martínez-Valverde S, Reyes-López A, et al. Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico. Salud Publica Mex. 2012;54(1):47–59.
   PubMed Web of Science ®Google Scholar
• Fernandes RRA. Cost-effectiveness of palivizumab use in high risk children from Brazilian health system perspective. Value Health. 2014;17(7):PA510.
   Web of Science ®Google Scholar
• Yekta Oncel M, Mutlu B, Kavurt S, et al. Respiratory syncytial virus prophylaxis in preterm Infants: a cost-effectiveness study from Turkey. Turk J Pediatr. 2012;54(4):344–351.
   PubMed Web of Science ®Google Scholar
• Fariña D, Rodríguez SP, Bauer G, et al. Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina. Pediatr Infect Dis J. 2002;21(4):287–291.
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Infectious Diseases. American academy of pediatrics bronchiolitis guidelines committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):415–420.
   PubMedGoogle Scholar
• Munoz FM, Ralston SL, Meer HC. RSV recommendations unchanged after review of new data. AAP News. 2017;38:1–4.
   Google Scholar
• Figueras Aloy J, Carbonell Estrany X, Comité de Estándares de la S. Actualización de las recomendaciones de la Sociedad Española de Neonatología para la utilización del palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial. Anales de Pediatría. 2015;82(199):e1–2.
   PubMedGoogle Scholar
• Bollani L, Baraldi E, Chirico G, et al. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital J Pediatr. 2015;41:97.
   PubMed Web of Science ®Google Scholar
• Wang DY, Li A, Paes B, et al. First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015). Eur J Pediatr. 2017;176(3):413–422.
   PubMed Web of Science ®Google Scholar
• Friedman D, Fryzek J, Jiang X, et al. Respiratory syncytial virus hospitalization risk in the second year of life by specific congenital heart disease diagnoses. PLoS One. 2017;12(3):e0172512.
   PubMed Web of Science ®Google Scholar
• Friedman D, Wong PC. Risk of respiratory syncytial virus hospitalization in the first and second years of life in pediatric patients with congenital heart disease. Pediatr Cardiol. 2017;38(6):1311–1312.
   PubMed Web of Science ®Google Scholar
• Green RJ, Zar HJ, Jeena PM, et al. South African guideline for the diagnosis, management and prevention of acute viral bronchiolitis in children. S Afr Med J. 2010;100(5):320. 322–5.
   PubMed Web of Science ®Google Scholar
• Türk Neonatoloji Derneği Palivizumab Proflaksisi Önerileri 12-08-2014. http://www.neonatology.org.tr/wp-content/uploads/2016/12/palivizumab.pdf, accessed on 19th June 2020.
   Google Scholar
• Medrano López C, García-Guereta L, Fernández Pineda L, et al. [Clinical consensus on respiratory syncytial virus (RSV) infection prophylaxis and the use of palivizumab in paediatric cardiology]. An Pediatr (Barc). 2010;72(6):432.e1-13.
   PubMed Web of Science ®Google Scholar
• Tulloh RMR, Medrano-Lopez C, Checchia PA, et al. CHD and respiratory syncytial virus: global expert exchange recommendations. Cardiol Young. 2017;27(8):1504–1521.
   PubMed Web of Science ®Google Scholar
• Chan P, Li A, Paes B, et al. Adherence to palivizumab for respiratory syncytial virus prevention in the Canadian registry of Palivizumab. Pediatr Infect Dis J. 2015;34(12):e290–7.
   PubMed Web of Science ®Google Scholar
• Borecka R, Lauterbach R, Helwich E, et al. Factors related to compliance with palivizumab prophylaxis for respiratory syncytial virus (RSV) infection - data from Poland. Dev Period Med. 2016;20(3):181–190.
   PubMedGoogle Scholar
• Krilov LR, Masaquel AS, Weiner LB, et al. Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis. BMC Pediatr. 2014;14:261.
   PubMed Web of Science ®Google Scholar
• Stewart DL, Ryan KJ, Seare JG, et al. Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured infants: a retrospective claims analysis. BMC Infect Dis. 2013;13:334.
   PubMed Web of Science ®Google Scholar
• Lessler J, Reich NG, Brookmeyer R, et al. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9(5):291–300.
   PubMed Web of Science ®Google Scholar
• El Saleeby CM, Bush AJ, Harrison LM, et al. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis. 2011;204(7):996–1002.
   PubMed Web of Science ®Google Scholar
• Garcia-Mauriño C, Moore-Clingenpeel M, Thomas J, et al. Viral load dynamics and clinical disease severity in infants with respiratory syncytial virus infection. J Infect Dis. 2019;219(8):1207–1215.
   PubMed Web of Science ®Google Scholar
• Uusitupa E, Waris M, Heikkinen T. Association of viral load with disease severity in outpatient children with respiratory syncytial virus infection. J Infect Dis. 2020;222(2):298–304.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Formica MA, Walsh EE. Diagnosis of respiratory syncytial virus infection: comparison of reverse transcription-PCR to viral culture and serology in adults with respiratory illness. J Clin Microbiol. 2002;40(3):817–820.
   PubMed Web of Science ®Google Scholar
• Haynes AK, Prill MM, Iwane MK, et al. Respiratory syncytial virus–United States, July 2012-June 2014. MMWR Morb Mortal Wkly Rep. 2014;63(48):1133–1136.
   PubMed Web of Science ®Google Scholar
• Rabon-Stith KM, Balderston McGuiness C, Saunders B, et al. Laboratory testing trends for respiratory syncytial virus, 2007–2011. J Clin Virol. 2013;58(3):575–578.
   PubMed Web of Science ®Google Scholar
• Nicholson EG, Munoz FM. A review of therapeutics in clinical development for respiratory syncytial virus and influenza in children. Clin Ther. 2018;40(8):1268–1281.
   PubMed Web of Science ®Google Scholar
• Xing Y, Proesmans M. New therapies for acute RSV infections: where are we? Eur J Pediatr. 2019;178(2):131–138.
   PubMed Web of Science ®Google Scholar
• Boyoglu-Barnum S, Tripp RA. Up-to-date role of biologics in the management of respiratory syncytial virus. Expert Opin Biol Ther. 2020;20(9):1073–1082.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Christine Koval C, John P DeVincenzo JP, et al. Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons. Transpl Infect Dis. 2017;19(2):e12657. Epub 2017 Mar 6.
   PubMed Web of Science ®Google Scholar
• Ark Biosciences reports successful completion of phase II proof-of-concept clinical trial of ziresovir for treatment of infants hospitalized with respiratory syncytial virus (RSV) infection. https://www.businesswire.com/news/home/20191105005042/en/, accessed on 12th September 2020.
   Google Scholar
• Viral inhibition in children for treatment of RSV (VICTOR). https://clinicaltrials.gov/ct2/show/study/NCT02654171?term=AK0529&draw=2&rank=7, accessed on 12th September 2020.
   Google Scholar
• A study of AK0529 in Chinese infants hospitalized with RSV (AirFLO). https://clinicaltrials.gov/ct2/show/NCT04231968?term=AK0529&draw=2&rank=1, accessed on 12th September 2020.
   Google Scholar
• Stevens M, Rusch S, DeVincenzo J, et al. Antiviral activity of oral JNJ-53718678 in healthy adult volunteers challenged with respiratory syncytial virus: a placebo-controlled study. J Infect Dis. 2018;218(5):748–756.
   PubMed Web of Science ®Google Scholar
• Study to evaluate safety and antiviral activity of doses of JNJ-53718678 in children (≥28 Days to ≤3 Years) with respiratory syncytial virus infection. https://clinicaltrials.gov/ct2/show/NCT03656510?term=JNJ-53718678&draw=2&rank=4, accessed on 12th September 2020.
   Google Scholar
• A two-part infant study for early diagnosis of respiratory syncytial virus (RSV) and evaluation of JNJ-53718678 in RSV acute respiratory tract disease. https://clinicaltrials.gov/ct2/show/NCT04068792?term=JNJ-53718678&draw=3&rank=13, accessed on 12th September 2020.
   Google Scholar
• Pre-approval access to JNJ-53718678 for the treatment of respiratory syncytial virus (RSV) infection in (a) immunocompromised adult and pediatric participants. https://clinicaltrials.gov/ct2/show/NCT04221412?term=JNJ-53718678&draw=2&rank=5, accessed on 12th September 2020.
   Google Scholar
• DeVincenzo JP, Whitley RJ, Mackman RL, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med. 2014;371(8):711–722.
   PubMed Web of Science ®Google Scholar
• Chemaly RF, Dadwal SS, Bergeron A, et al. A phase 2, randomized, double-blind, placebo-controlled trial of presatovir for the treatment of respiratory syncytial virus upper respiratory tract infection in hematopoietic-cell transplant recipients. Clin Infect Dis. 2019;ciz1166. DOI:10.1093/cid/ciz1166
   PubMedGoogle Scholar
• Safety study of GS-5806 to treat respiratory syncytial virus (RSV). https://clinicaltrials.gov/ct2/show/NCT01797419?term=GS-5806&draw=2&rank=3, accessed on 12th September 2020.
   Google Scholar
• Safety, efficacy and pharmacokinetics of BTA-C585 in a RSV viral challenge study. https://clinicaltrials.gov/ct2/show/NCT02718937?term=BTA-C585&draw=2&rank=3, accessed on 12th September 2020.
   Google Scholar
• DeVincenzo J, Tait D, Efthimiou J, et al. A randomized, placebo-controlled, respiratory syncytial virus human challenge study of the antiviral efficacy, safety, and pharmacokinetics of RV521, an inhibitor of the RSV-F protein. Antimicrob Agents Chemother. 2020;64(2):e01884–19.
   PubMed Web of Science ®Google Scholar
• A study in Infants with RSV LRTI to evaluate RV521 (REVIRAL 1). https://clinicaltrials.gov/ct2/show/NCT04225897?term=RV521&draw=2&rank=2, accessed on 12th September 2020.
   Google Scholar
• MicroDose Therapeutx announces conclusion of MDT-637 Phase I single and multiple ascending dose studies in healthy volunteers for treatment of respiratory syncytial virus (RSV). https://www.businesswire.com/news/home/20120424005631/en/MicroDose-Therapeutx-Announces-Conclusion-MDT-637-Phase-Single, accessed on 12th September 2020.
   Google Scholar
• MicroDose Therapeutx announces successful conclusion of safety study in asthmatic patients for MDT-637 and presentation of overall Phase 1 results at the 8th annual international respiratory syncytial virus (RSV) symposium. https://www.businesswire.com/news/home/20120928005136/en/MicroDose-Therapeutx-Announces-Successful-Conclusion-Safety-Study, accessed on 12th September 2020.
   Google Scholar
• Eoin Coakley E, Ahmad A, Larson K, et al. LB6. EDP-938, a novel RSV N-inhibitor, administered once or twice Daily was safe and demonstrated robust antiviral and clinical efficacy in a healthy volunteer challenge study. Open Forum Infect Dis. 2016;6(Suppl.2):S995.
   Google Scholar
• DeVincenzo JP, McClure MW, Symons JA, et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med. 2015;373(21):2048–2058.
   PubMed Web of Science ®Google Scholar
• A study of ALS-008176 in infants hospitalized with RSV. https://clinicaltrials.gov/ct2/show/NCT02202356?term=ALS-008176&draw=2&rank=6, accessed on 12th September 2020.
   Google Scholar
• A study to evaluate the antiviral activity, clinical outcomes, safety, tolerability, and pharmacokinetics of orally administered lumicitabine (JNJ-64041575) regimens in hospitalized infants and children aged 28 days to 36 months infected with respiratory syncytial virus. https://clinicaltrials.gov/ct2/show/results/NCT03333317?term=Lumicitabine&draw=2&rank=1, accessed on 12th September 2020.
   Google Scholar
• A study of PC786 to evaluate the antiviral activity, safety and pharmacokinetics of multiple doses in an RSV challenge study. https://clinicaltrials.gov/ct2/show/NCT03382431?term=PC786&draw=2&rank=1, accessed on 12th September 2020.
   Google Scholar
• DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA. 2010;107(19):8800–8805.
   PubMed Web of Science ®Google Scholar
• Zamora MR, Budev M, Rolfe M, et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med. 2011;183(4):531–538.
   PubMed Web of Science ®Google Scholar
• Gottlieb J, Zamora MR, Hodges T, et al. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. J Heart Lung Transplant. 2016;35(2):213–221.
   PubMed Web of Science ®Google Scholar
• Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4(6):477–487.
   PubMed Web of Science ®Google Scholar
• Moses E, Zeldin RK, de Fougerolles A Results from the first-in-infant phase I/IIa study with the anti-RSV Nanobody, ALX-0171. Webcast Presentation. 3 May 2016;- Zwijnaarde, Belgium
   Google Scholar
• Evaluation of ALX-0171 in Japanese children hospitalized for respiratory syncytial virus lower respiratory tract infection. https://clinicaltrials.gov/ct2/show/NCT03418571, accessed on 5th June 2020.
   Google Scholar
• Food and Drug Administration. Ribavirin aerosol approved for severe cases of RSV in infants and young children. FDA Drug Bull. 1986;16(1):7.
   Google Scholar
• Synagis® (palivizumab) for Intramuscular Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/palimed102302LB.pdf, accessed on 11th September 2020.
   Google Scholar
• Alansari K, Hassan Toaimah F, Helmi Almatar D, et al. Monoclonal antibody treatment of RSV bronchiolitis in young infants: a randomized trial. Pediatrics. 2019;143(3):e20182308.
   PubMed Web of Science ®Google Scholar
• Rowan CM, Gertz SJ, Zinter MS, et al. A multicenter investigation of respiratory syncytial viral infection in children with hematopoietic cell transplantation. Transpl Infect Dis. 2018;20(3):e12882.
   PubMed Web of Science ®Google Scholar
• Danziger-Isakov LA, Arslan D, Sweet S, et al. RSV prevention and treatment in pediatric lung transplant patients: a survey of current practices among the International pediatric lung transplant collaborative. Pediatr Transplant. 2012;16(6):638–644.
   PubMed Web of Science ®Google Scholar
• Anak S, Atay D, Unuvar A, et al. Respiratory syncytial virus infection outbreak among pediatric patients with oncologic diseases and/or BMT. Pediatr Pulmonol. 2010;45(3):307–311.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Auad JP, Nava-Frías M, Casasola-Flores J, et al. The epidemiology and clinical characteristics of respiratory syncytial virus infection in children at a public pediatric referral hospital in Mexico. Int J Infect Dis. 2012;16(7):e508–13.
   PubMed Web of Science ®Google Scholar
• PATH. RSV vaccine and mAB snapshot, March 26, 2020. https://vaccineresources.org/files/RSV-snapshot-2020_03_26_High%20Resolution_PDF.pdf, accessed on 2020 May 20th.
   Google Scholar
• PATH. RSV vaccine and mAB snapshot, August 28, 2019. https://path.azureedge.net/media/documents/RSV-snapshot-2019_08_28_High_Resolution_PDF.pdf, accessed on 2020 May 20th.
   Google Scholar
• Mejias A, Rodríguez-Fernández R, Oliva S, et al. The journey to a respiratory syncytial virus vaccine. Ann Allergy Asthma Immunol. 2020;S1081–1206(20):30175–30177.
   Google Scholar
• Zhu Q, Jason S McLellan JS, Kallewaard NL, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017;9(388):eaaj1928.
   PubMed Web of Science ®Google Scholar
• Maas B, Aliprantis A, Wolford D, et al. 1384. RSV monoclonal antibody (MK-1654) Phase 1 pharmacokinetics (PK) in healthy adults and population PK modeling to support pediatric development. Open Forum Infect Dis. 2018;5(Suppl1):S424–5.
   Google Scholar
• Domachowske JB, Khan AA, Esser MT, et al. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatr Infect Dis J. 2018;37(9):886–892.
   PubMed Web of Science ®Google Scholar
• A study to evaluate the safety of MEDI8897 for the prevention of medically attended respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in high-risk children. https://clinicaltrials.gov/ct2/show/NCT03959488, accessed on 5th June 2020.
   Google Scholar
• Griffin MP, Yuan Y, Takas T, et al. 901. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383(5):415–425.
   PubMed Web of Science ®Google Scholar
• Safety, tolerability, and pharmacokinetics of MK-1654 in infants (MK-1654-002). https://clinicaltrials.gov/ct2/show/NCT03524118?term=NCT03524118&draw=2&rank=1, accessed on 5th June 2020.
   Google Scholar
• A study to evaluate the safety and ffficacy of MEDI8897 for the prevention of medically attended RSV LRTI in healthy late preterm and term infants (MELODY). https://clinicaltrials.gov/ct2/show/NCT03979313?term=NCT03979313&draw=2&rank=1, accessed on 7th September 2020.
   Google Scholar
• US FDA grants breakthrough therapy designation for potential next-generation RSV medicine MEDI8897. https://www.astrazeneca.com/media-centre/press-releases/2019/us-fda-grants-breakthrough-therapy-designation-for-potential-next-generation-rsv-medicine-medi8897.html, accessed on 5th June 2020.
   Google Scholar
• Wright PF, Karron RA, Belshe RB, et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine. 2007;25(42):7372–7378.
   PubMed Web of Science ®Google Scholar
• Rey GU, Miao C, Caidi H, et al. Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice. PLoS One. 2013;8(12):e83075.
   PubMed Web of Science ®Google Scholar
• Polack FP. The changing landscape of respiratory syncytial virus. Vaccine. 2015;33(47):6473–6478.
   PubMed Web of Science ®Google Scholar
• Messeret ES, Masresha B, Yakubu A, et al. Maternal and Neonatal Tetanus Elimination (MNTE) in the WHO African Region. J Immunol Sci. 2018;Suppl(15):103–107.
   Google Scholar
• Romanin V, Acosta AM, Juarez MDV, et al. Maternal vaccination in Argentina: tetanus, diphtheria, and acellular pertussis vaccine effectiveness during pregnancy in preventing pertussis in infants <2 months of age. Clin Infect Dis. 2020;70(3):380–387.
   PubMed Web of Science ®Google Scholar
• August A, Glenn GM, Kpamegan E, et al. A phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. Vaccine. 2017;35(30):3749–3759.
   PubMed Web of Science ®Google Scholar
• Schmoele-Thoma B, Falsey AR, Walsh EE, et al. 2755 phase 1/2, first-in-human study of the safety, tolerability, and immunogenicity of an RSV prefusion F-based subunit vaccine candidate. Open Forum Infect Dis. 2019;6(Suppl 2):S970.
   Google Scholar
• Beran J, Lickliter JD, Schwarz TF, et al. Safety and immunogenicity of 3 formulations of an investigational respiratory syncytial virus vaccine in nonpregnant women: results from 2 phase 2 trials. J Infect Dis. 2018;217(10):1616–1625.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Polack FP, Piedra PA, et al. Respiratory syncytial virus vaccination during pregnancy and effects in infants. N Engl J Med. 2020;383(5):426–439.
   PubMed Web of Science ®Google Scholar
• A study to determine the safety and efficacy of the RSV F vaccine to protect infants via maternal immunization. https://clinicaltrials.gov/ct2/show/NCT02624947/, accessed on 8th June 2020.
   Google Scholar
• Novavax. Press release: novavax announces topline RSV F vaccine data from two clinical trials in older adults. https://ir.novavax.com/news-releases/news-release-details/novavax-announces-topline-rsv-f-vaccine-data-two-clinical-trials#, accessed on 20th May 2020.
   Google Scholar
• Baglivo SJ, Polack FP. The long road to protect infants against severe RSV lower respiratory tract illness. F1000Res. 2019;8: F1000. Faculty Rev-610.
   PubMedGoogle Scholar
• A phase 2B placebo-controlled, randomized study of a respiratory syncytial virus (RSV) vaccine in pregnant women. https://clinicaltrials.gov/ct2/show/NCT04032093, accessed on 8th June 2020.
   Google Scholar
• Study of safety, reactogenicity and immunogenicity of GlaxoSmithKline’s (GSK) respiratory syncytial virus (RSV) maternal unadjuvanted vaccine in healthy pregnant women (Aged 18 to 40 Years) and their infants. https://clinicaltrials.gov/ct2/show/NCT04126213, accessed on 8th June 2020.
   Google Scholar
• Chu HY, Steinhoff MC, Magaret A, et al. Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh. J Infect Dis. 2014;210(10):1582–1589.
   PubMed Web of Science ®Google Scholar
• Piedra PA, Jewell AM, Cron SG, et al. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine. 2003;21(24):3479–3482.
   PubMed Web of Science ®Google Scholar
• Chu HY, Katz J, Tielsch J, et al. Respiratory syncytial virus infection in infants in rural Nepal. J Infect. 2016;73(2):145–154.
   PubMed Web of Science ®Google Scholar
• Nyiro JU, Sande CJ, Mutunga M, et al. Absence of association between cord specific antibody levels and severe respiratory syncytial virus (RSV) disease in early infants: a case control study from coastal Kenya. PLoS One. 2016;11(11):e0166706.
   PubMed Web of Science ®Google Scholar
• Muňoz FM, Swamy GK, Hickman SP, et al. Safety and immunogenicity of a respiratory syncytial virus fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants. J Infect Dis. 2019;220(11):1802–1815.
   PubMed Web of Science ®Google Scholar
• Yildiz M, Kara M, Sutcu M, et al. Evaluation of respiratory syncytial virus IgG antibody dynamics in mother-infant pairs cohort. Eur J Clin Microbiol Infect Dis. 2020;39(7):1279–1286.
   PubMed Web of Science ®Google Scholar
• Fouda GG, Martinez DR, Swamy GK, et al. The impact of IgG transplacental transfer on early life immunity. Immunohorizons. 2018;2(1):14–25.
   PubMedGoogle Scholar
• Niewiesk S. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol. 2014;5:446.
   PubMed Web of Science ®Google Scholar
• Arankalle VA, Kulkarni R, Malshe N, et al. Seroepidemiology of respiratory syncytial virus in Western India with special reference to appropriate age for infant vaccination. J Med Virol. 2019;91(8):1566–1570.
   PubMed Web of Science ®Google Scholar
• Zimmermann P, Perrett KP, Messina NL, et al. The effect of maternal immunisation during pregnancy on infant vaccine responses. EClinicalMedicine. 2019;13:21–30.
   PubMedGoogle Scholar
• Duke T, English M, Carai S, et al. Paediatric care in the time of COVID-19 in countries with under-resourced healthcare systems. Arch Dis Child. 2020;105(7):616–617.
   PubMed Web of Science ®Google Scholar
• Commitment and call to action: global collaboration to accelerate new COVID-19 health technologies. A global collaboration to accelerate the development, production and equitable access to new COVID-19 diagnostics, therapeutics and vaccines. https://www.who.int/news-room/detail/24-04-2020-commitment-and-call-to-action-global-collaboration-to-accelerate-new-covid-19-health-technologies, accessed on 23rd June 2020.
   Google Scholar
• COVID-19: lessons for international research collaboration and information exchange. An ICC statement supporting multilateral and multistakeholder scientific collaboration to address COVID-19 and future pandemics. https://iccwbo.org/publication/covid-19-lessons-for-international-research-collaboration-and-information-exchange/, accessed on 23rd June 2020.
   Google Scholar
• EU global response to COVID-19. https://ec.europa.eu/international-partnerships/topics/eu-global-response-covid-19_en, accessed on 23rd June 2020.
   Google Scholar
• End Polio. https://my.rotary.org/en/take-action/end-polio, accessed on 23rd June 2020.
   Google Scholar
• Polio global eradication initiative. http://polioeradication.org/who-we-are/, accessed on 23rd June 2020.
   Google Scholar
• Li X, Willem L, Antillon M, et al. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries. BMC Med. 2020;18(1):82.
   PubMed Web of Science ®Google Scholar
• RSV surveillance case definitions. https://www.who.int/influenza/rsv/rsv_case_definition/en/, accessed on 7th September 2020.
   Google Scholar
• Nasreen S, Luby SP, Brooks WA, et al. Population-based incidence of severe acute respiratory virus infections among children aged <5 years in rural Bangladesh, june-october 2010. PLoS One. 2014;9(2):e89978.
   PubMed Web of Science ®Google Scholar
• Jullien S, Pradhan D, Tshering T, et al. Pneumonia in children admitted to the national referral hospital in Bhutan: A prospective cohort study. Int J Infect Dis. 2020;95:74–83.
   PubMed Web of Science ®Google Scholar
• Ouédraogo S, Traoré B, Nene BZA, et al. Viral etiology of respiratory tract infections in children at the pediatric hospital in Ouagadougou (Burkina Faso). PLoS One. 2014;9(10):e110435.
   PubMed Web of Science ®Google Scholar
• Mackenzie GA, AminataVilane A, Salaudeen R, et al. Respiratory syncytial, parainfuenza and infuenza virus infection in young children with acute lower respiratory infection in rural Gambia. Sci Rep. 2019;9:17965.
   PubMed Web of Science ®Google Scholar
• Stensballe LG, Trautner S, Kofoed PE, et al. Comparison of nasopharyngeal aspirate and nasal swab specimens for detection of respiratory syncytial virus in different settings in a developing country. Trop Med Int Health. 2002;7(4):317–321.
   PubMed Web of Science ®Google Scholar
• Nguyen VH, Dubot-Pérès A, Russell FM, et al. Acute respiratory infections in hospitalized children in Vientiane, Lao PDR - the importance of respiratory syncytial virus. Sci Rep. 2017;7(1):9318.
   PubMedGoogle Scholar
• Rabarison JH, Tempia S, Harimanana A, et al. Burden and epidemiology of influenza- and respiratory syncytial virus-associated severe acute respiratory illness hospitalization in Madagascar, 2011-2016. Influenza Other Respir Viruses. 2019;13(2):138–147.
   PubMed Web of Science ®Google Scholar
• Peterson I, Bar-Zeev N, Kennedy N, et al. Respiratory virus-associated severe acute respiratory illness and viral clustering in Malawian children in a setting with a high prevalence of HIV infection, malaria, and malnutrition. J Infect Dis. 2016;214(11):1700–1711.
   PubMed Web of Science ®Google Scholar
• Bénet T, Sylla M, Messaoudi M, et al. Etiology and factors associated with pneumonia in children under 5 years of age in Mali: a prospective case-control study. PLoS One. 2015;10(12):e0145447.
   PubMed Web of Science ®Google Scholar
• Loscertales MP, Roca A, Ventura PJ, et al. Epidemiology and clinical presentation of respiratory syncytial virus infection in a rural area of Southern Mozambique. Pediatr Infect Dis J. 2002;21(2):148–155.
   PubMed Web of Science ®Google Scholar
• Turner C, Turner P, Cararra V, et al. A high burden of respiratory syncytial virus associated pneumonia in children less than two years of age in a South East Asian refugee population. PLoS One. 2012;7(11):e50100.
   PubMed Web of Science ®Google Scholar
• Lagare A, Ousmane S, Dan Dano I, et al. Molecular detection of respiratory pathogens among children aged younger than 5 years hospitalized with febrile acute respiratory infections: a prospective hospital-based observational study in Niamey, Niger. Health Sci Rep. 2019;2(11):e137.
   PubMedGoogle Scholar
• Fall A, Dia N, Cisse El HA, et al. Epidemiology and molecular characterization of human respiratory syncytial virus in Senegal after four consecutive years of surveillance, 2012-2015. PLoS One. 2016;11(6):e0157163.
   PubMed Web of Science ®Google Scholar
• Agoti CN, Mayieka LM, Otieno JR, et al. Examining strain diversity and phylogeography in relation to an unusual epidemic pattern of respiratory syncytial virus (RSV) in a long-term refugee camp in Kenya. BMC Infect Dis. 2014;14:178.
   PubMed Web of Science ®Google Scholar
• Sawatzky J, Soo J, Conroy AL, et al. Biomarkers of systemic inflammation in Ugandan infants and children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J. 2019;38(8):854–859.
   PubMed Web of Science ®Google Scholar
• Al-Sonboli N, Hart CA, Al-Aeryani A, et al. Respiratory syncytial virus and human metapneumovirus in children with acute respiratory infections in Yemen. Pediatr Infect Dis J. 2005;24(8):734–736.
   PubMed Web of Science ®Google Scholar
• Bénet T, Sánchez Picot V, Messaoudi M, et al. Microorganisms associated with pneumonia in children <5 years of age in developing and emerging countries: the GABRIEL pneumonia multicenter, prospective, case-control study. Clin Infect Dis. 2017;65(4):604–612.
   PubMed Web of Science ®Google Scholar
• Feikin DR, Fu W, Park DE, et al. Is higher viral load in the upper respiratory tract associated with severe pneumonia? Findings from the PERCH study. Clin Infect Dis. 2017;64(suppl_3):S337–46.
   PubMedGoogle Scholar
• Ghazaryan H, Babloyan A, Sarkissian A, et al. Respiratory syncytial and influenza virus detecting rapid tests in children younger than 5 years of age in Armenia. J Infect Dev Ctries. 2019 May 16;13(5.1):75S–80S.
   PubMed Web of Science ®Google Scholar
• Njouom R, Yekwa EL, Cappy P, et al. Viral etiology of influenza-like illnesses in Cameroon, january-december 2009. J Infect Dis. 2012;206(Suppl 1):S29–35.
   PubMedGoogle Scholar
• Kadjo HA, Ekaza E, Coulibaly D, et al. Sentinel surveillance for influenza and other respiratory viruses in Côte d’Ivoire, 2003-2010. Influenza Other Respir Viruses. 2013;7(3):296–303.
   PubMed Web of Science ®Google Scholar
• Hatem A, Mohamed S, Abu Elhassan UE, et al. Clinical characteristics and outcomes of patients with severe acute respiratory infections (SARI): results from the Egyptian surveillance study 2010-2014. Multidiscip Respir Med. 2019;14:11.
   PubMed Web of Science ®Google Scholar
• Chakhunashvili G, Wagner AL, Power LE, et al. Severe acute respiratory infection (SARI) sentinel surveillance in the country of Georgia, 2015-2017. PLoS One. 2018;13(7):e0201497.
   PubMed Web of Science ®Google Scholar
• Adiku TK, Asmah RH, Rodrigues O, et al. Aetiology of acute lower respiratory infections among children under five years in Accra, Ghana. Pathogens. 2015;4(1):22–33.
   PubMed Web of Science ®Google Scholar
• McCracken JP, Arvelo W, Ortíz J, et al. Comparative epidemiology of human metapneumovirus- and respiratory syncytial virus-associated hospitalizations in Guatemala. Influenza Other Respir Viruses. 2014;8(4):414–421.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Kumar R, Broor S, et al. Epidemiology of viral acute lower respiratory infections in a community-based cohort of rural North Indian children. J Glob Health. 2019 Jun;9(1):010433.
   PubMed Web of Science ®Google Scholar
• Nokes DJ, Okiro EA, Ngama M, et al. Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi district, Kenya. Clin Infect Dis. 2008;46(1):50–57.
   PubMed Web of Science ®Google Scholar
• Chaw L, Kamigaki T, Burmaa A, et al. Burden of influenza and respiratory syncytial virus infection in pregnant women and infants under 6 months in Mongolia: a prospective cohort study. PLoS One. 2016;11(2):e0148421.
   PubMed Web of Science ®Google Scholar
• Jroundi I, Mahraoui C, Benmessaoud R, et al. A comparison of human metapneumovirus and respiratory syncytial virus WHO-defined severe pneumonia in Moroccan children. Epidemiol Infect. 2016;144(3):516–526.
   PubMed Web of Science ®Google Scholar
• Oladele DM, Oladele DP, Ibraheem RM, et al. Reappraisal of respiratory syncytial virus as an aetiology of severe acute lower respiratory tract infections in children younger than 5 years in Nigeria. Trans R Soc Trop Med Hyg. 2019;113(8):446–452.
   PubMed Web of Science ®Google Scholar
• Chidlow GR, Laing IA, Harnett GB, et al. Respiratory viral pathogens associated with lower respiratory tract disease among young children in the highlands of Papua New Guinea. J Clin Virol. 2012;54(3):235–239.
   PubMed Web of Science ®Google Scholar
• Ueno F, Tamaki R, Saito M, et al. Age-specific incidence rates and risk factors for respiratory syncytial virus-associated lower respiratory tract illness in cohort children under 5 years old in the Philippines. Influenza Other Respir Viruses. 2019;13(4):339–353.
   PubMed Web of Science ®Google Scholar
• Sampath Jayaweera JAA, Reyes M. Childhood nosocomial viral acute respiratory tract infections in teaching hospital Anuradhapura, Sri Lanka. BMC Res Notes. 2019;12(1):581.
   PubMedGoogle Scholar
• Brini I, Guerrero A, Hannachi N, et al. Epidemiology and clinical profile of pathogens responsible for the hospitalization of children in Sousse area, Tunisia. PLoS One. 2017;12(11):e0188325.
   PubMed Web of Science ®Google Scholar
• Do LA, Bryant JE, Tran AT, et al. Respiratory syncytial virus and other viral infections among children under two years old in Southern Vietnam 2009-2010: clinical characteristics and disease severity. PLoS One. 2016 Aug 8;11(8):e0160606.
   PubMed Web of Science ®Google Scholar
• Biggs H, Simoes EA, Abu-Khader IB, et al. 2629. Respiratory syncytial virus epidemiology and factors associated with severity among hospitalized infants in four middle-income countries, 2015–2017. Open Forum Infect Dis. 2019;6(S2):S917–8.
   Google Scholar
• Laguna-Torres VA, Sánchez-Largaespada JF, Lorenzana I, et al. Influenza and other respiratory viruses in three Central American countries. Influenza Other Respir Viruses. 2011;5(2):123–134.
   PubMed Web of Science ®Google Scholar
• Derrar F, Izri K, Kaddache C, et al. Virologic study of acute lower respiratory tract infections in children admitted to the paediatric department of Blida university hospital, Algeria. New Microbes New Infect. 2019;30:100536.
   PubMedGoogle Scholar
• Maksić H, Heljić S, Skokić F, et al. Predictors and incidence of hospitalization due to respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in non-prophylaxed moderate-to-late preterm infants in Bosnia and Herzegovina. Bosn J Basic Med Sci. 2018;18(3):279–288.
   PubMed Web of Science ®Google Scholar
• Kelly MS, Smieja M, Luinstra K, et al. Association of respiratory viruses with outcomes of severe childhood pneumonia in Botswana. PLoS One. 2015;10(5):e0126593.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Martínez CE, Rodríguez DA, Nino G. Respiratory syncytial virus, adenoviruses, and mixed acute lower respiratory infections in children in a developing country. J Med Virol. 2015;87(5):774–781.
   PubMed Web of Science ®Google Scholar
• Jonnalagadda S, Rodríguez O, Estrella B, et al. Etiology of severe pneumonia in Ecuadorian children. PLoS One. 2017;12(2):e0171687.
   PubMed Web of Science ®Google Scholar
• Lekana-Douki SE, Nkoghe D, Drosten C, et al. Viral etiology and seasonality of influenza-like illness in Gabon, March 2010 to June 2011. BMC Infect Dis. 2014;14:373.
   PubMed Web of Science ®Google Scholar
• Gurgel RQ, Bezerra PG, Duarte Mdo C, et al. Relative frequency, possible risk factors, viral codetection rates, and seasonality of respiratory syncytial virus among children with lower respiratory tract infection in Northeastern Brazil. Medicine (Baltimore). 2016;95(15):e3090.
   PubMed Web of Science ®Google Scholar
• Luo HJ, Huang XB, Zhong HL, et al. Epidemiological characteristics and phylogenic analysis of human respiratory syncytial virus in patients with respiratory infections during 2011-2016 in Southern China. Int J Infect Dis. 2020;90:5–17.
   PubMed Web of Science ®Google Scholar
• Valdivia A, Savón C, Chacón D, et al. Analysis of respiratory syncytial virus in clinical samples by reverse transcriptase-polymerase chain reaction restriction mapping. Mem Inst Oswaldo Cruz. 1997;92(3):389–393.
   PubMed Web of Science ®Google Scholar
• Salimi V, Tavakoli-Yaraki M, Yavarian J, et al. Prevalence of human respiratory syncytial virus circulating in Iran. J Infect Public Health. 2016 Mar-Apr;9(2):125–135.
   PubMed Web of Science ®Google Scholar
• Hassan DA, Rachid SK, Ziebuhr J. A single-center study of viral respiratory tract infections in hospitalized children from the Kurdistan region of Iraq. Glob Pediatr Health. 2018;5:2333794X18784996.
   PubMedGoogle Scholar
• Abou-El-Hassan H, Massaad E, Soudani N, et al. Detection of ON1 and novel genotypes of human respiratory syncytial virus and emergence of palivizumab resistance in Lebanon. PLoS One. 2019;14(2):e0212687.
   PubMed Web of Science ®Google Scholar
• Khor CS, Sam IC, Hooi PS, et al. Epidemiology and seasonality of respiratory viral Infections in hospitalized children in Kuala Lumpur, Malaysia: a retrospective study of 27 years. BMC Pediatr. 2012;12:32.
   PubMed Web of Science ®Google Scholar
• Savić N, Janković B, Minić P, et al. Clinical characteristics of respiratory syncytial virus infection in neonates and young infants. Vojnosanit Pregl. 2011;68(3):220–224.
   PubMed Web of Science ®Google Scholar
• İzci Güllü E, Akın Y, Karaaslan A, et al. RSV infection in Istanbul: risk factors and frequency. J Infect Dev Ctries. 2017;11(9):691–696.
   PubMed Web of Science ®Google Scholar
• Rha B, Dahl RM, Moyes J, et al. Performance of surveillance case definitions in detecting respiratory syncytial virus infection among young children hospitalized with severe respiratory illness-South Africa, 2009-2014. J Pediatric Infect Dis Soc. 2019;8(4):325–333.
   PubMed Web of Science ®Google Scholar
• Chittaganpitch M, Waicharoen S, Yingyong T, et al. Viral etiologies of influenza-like illness and severe acute respiratory infections in Thailand. Influenza Other Respir Viruses. 2018;12(4):482–489.
   PubMed Web of Science ®Google Scholar
• Valero N, Larreal Y, Arocha F, et al. [Viral etiology of acute respiratory infections]. Invest Clin. 2009;50(3):359–368.
   PubMed Web of Science ®Google Scholar
• Edwards L, Boisson E, Nathaniel-Girdharrie SM, et al. Distribution of influenza and other acute respiratory viruses during the first year after the 2009-2010 influenza pandemic in the English- and Dutch-speaking Caribbean countries. Influenza Other Respir Viruses. 2013;7(6):1062–1069.
   PubMed Web of Science ®Google Scholar
• Nolan T, Borja-Tabora C, Lopez P, et al. Prevalence and incidence of respiratory syncytial virus and other respiratory viral infections in children aged 6 months to 10 years with influenza-like illness enrolled in a randomized trial. Clin Infect Dis. 2015;60(11):e80–9.
   PubMed Web of Science ®Google Scholar
• Hong T, Bolisetty S, Bajuk B, et al. A population study of respiratory rehospitalisation in very preterm infants in the first 3 years of life. J Paediatr Child Health. 2016;52(7):715–721.
   PubMed Web of Science ®Google Scholar
• Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr. 2003;143(5 Suppl):S150–6.
   PubMed Web of Science ®Google Scholar
• Moffett HF, Harms CK, Fitzpatrick KS, et al. B cells engineered to express pathogen-specific antibodies protect against infection. Sci Immunol. 2019;4(35):eaax0644.
   PubMed Web of Science ®Google Scholar